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ABSTRACT 
 
 Measures of disease activity are necessary when diagnosing and monitoring response 
to therapy in canine inflammatory bowel disease (IBD).  Endoscopy has been described as the 
gold standard to evaluate the mucosal surface and obtain biopsies for a histopathologic 
diagnosis.  Previous veterinary studies have failed to definitively determine the benefit of 
endoscopic gastrointestinal mucosal evaluation in defining disease severity in dogs with IBD.   
 The aim of the following thesis was to evaluate the inter-observer agreement between 
trainee and expert endoscopists in the assessment of mucosal lesions in dogs with IBD, and to 
evaluate if trained operators can identify and agree upon most endoscopic lesions of mucosal 
inflammation using the proposed simplified endoscopic scoring index. 
Archived images from endoscopic procedures performed in dogs diagnosed with IBD 
at the Iowa State Lloyd Veterinary Medical Center from 2002-2012 were reviewed. In total, 
95 images of inflammatory and normal mucosa from dogs with IBD were displayed to 3 
expert and 5 trainee endoscopists (initial test). Each picture was assessed independently by the 
endoscopist for inflammatory changes using established indices or interpreted as normal 
mucosa from multiple areas of the GI tract (ie. stomach, duodenum, and colon).  Agreement 
was measured between the trainee and expert endoscopists for each organ.  The developed 
index was then applied to a prospective independent group of dogs (23 total) diagnosed with 
inflammatory bowel disease for a validation study. Comparisons were made between 2 expert 
endoscopists (JES & AEJ) to measure mucosal assessment agreement. 
Regression analysis showed a significant (p<0.01) difference between expert versus 
trainee endoscopy scores in duodenal evaluation trial 1, although repeat duodenal lesion 
x 
 
evaluation aided by use of a visual template improved the overall scores of trainee 
endoscopists to near that of expert endoscopists (p=0.06). For the validation study, the expert 
endoscopists had substantial to almost perfect agreement for each lesion assessed in the 
stomach (k>0.8), had moderate to substantial agreement assessing the small intestine (k>0.6-
0.84) and substantial agreement when assessing the colon (k>0.7-1). The conclusion is that 
trained operators can identify and agree upon most endoscopic lesions of mucosal 
inflammation. 
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CHAPTER 1 
 INTRODUCTION:  
Background 
Inflammatory bowel disease (IBD) affects many species including humans, dogs, cats, 
and even rodent models have been used to study intestinal inflammation.  In dogs, IBD refers 
to a group of chronic enteropathies with persistent or recurrent clinical signs such as vomiting, 
diarrhea, alterations in appetite, and weight loss.
1-3  
Chronic enteropathies in dogs is a general 
term describing IBD, food responsive diarrhea (FRD), and antibiotic responsive diarrhea 
(ARD).
3-4
 FRD can be divided into two main causes; immunologic and nonimmunogic.
5 
 Non-
immunologic causes of FRD are instances of food intolerance and dietary indiscretion, versus 
immunologic in which a dietary hypersensitivity occurs.
5 
 These syndromes can have the same 
clinical signs as IBD and can sometimes be indistinguishable as some people theorize that 
IBD can cause FRD, or vice versa.
5  
ARD occurs when there are microbial imbalances in the 
gastrointestinal (GI) mucosa by a pathogenic species.
3 
 A potential cause for certain dogs to 
have ARD is  aberrant host-bacterial interactions.
6
 Certain dog breeds have been associated 
with ARD most notably the German Shepherd Dog.
6
  
Genetics and its role in gastrointestinal health have been an increasing area of research 
in veterinary medicine. There are distinct breed predispositions for canine chronic 
enteropathies that have been investigated. Some of these include immunoproliferative 
enteropathy in Basenjis, protein losing enteropathy and nephropathy in Soft-Coated Wheaten 
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Terriers, and Boxer granulomatous colitis.
3,7 
 Additionally, Yorkshire terriers exhibit an 
increased prevalence of intestinal lymphangiectasia suggesting a possible genetic association. 
As already stated, chronic enteropathies present with similar signs.  When clinicians 
evaluate dogs for signs of chronic vomiting or diarrhea, it is important to rule out primary GI 
causes from non-GI causes.   Clinicians perform a battery of tests including bloodwork, fecal 
analysis, and abdominal imaging, to try and differentiate these different causes since therapy 
varies in each instance.  Once the non-GI causes for the clinical signs such as endocrine, 
kidney, and liver disorders have been ruled out, further GI diagnostic investigation is 
warranted.  
When dogs have diarrhea, it is important to distinguish between a small and/or a large 
bowel origin.
3,7  
Large bowel diarrhea is often characterized by tenesmus, a small volume of 
feces with mucus or frank blood present, and an increased frequency in defecation.  Dogs with 
small bowel diarrhea have a larger stool volume, weight loss, and may also present with signs 
of vomiting.  Small bowel diarrhea is a common clinical sign of dogs diagnosed with IBD.
7 
Questions that are often asked of the owner of these patients include volume of stool 
produced, frequency of defecation, straining, and the presence of blood or mucus in the stool.
4
  
The answers to these questions allow the clinician to often localize the source of the intestinal 
problem. Once it is determined which area of the GI tract is affected (based on clinical signs 
and laboratory tests [ie, hypocobalaminemia])), GI endoscopy is often the next diagnostic 
step.
2 
In order to obtain a diagnosis of IBD, one must exclude other causes of intestinal 
disease and obtain mucosal biopsies that demonstrate  histopathologic evidence of mucosal 
inflammation.
1-4  
While the exact etiopathogenesis of IBD in dogs is unknown, disruption of 
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the GI mucosa, alterations in the GI microbiota (dysbiosis), and dysregulation of  mucosal 
immunity have been implicated.
1-5  
 The normal functioning GI tract has inherent protective 
mechanisms including the gut associated lymphoid tissue (GALT), development of oral 
tolerance, and the production of IgA.
3,8 
The current hypotheses  in human, murine, and canine 
models of IBD suggest that genetics, the mucosal immune system, diet, and disruption of the 
GI microbiota can be contributing factors to disease.
3,8 
 
In the normal animal, antigen presenting cells (APCs) continually sample antigens 
within the lumen of the GI tract.
8
  Pending the type of antigen, signals created by the APCs 
stimulate the adaptive immune response to eradicate the pathogen.
8 
Presentation of the antigen 
to the lymphocyte induces lymphocyte activation.
3 
Further activation signals from the APC 
and helper T cells occur, which induce sensitized effector T lymphocytes to travel through the 
mesenteric lymph nodes via lymphatic drainage and return to the lamina propria beneath the 
GI mucosal epithelium.
3 
Here, they are primed to respond to a given antigen they have been 
exposed. 
In IBD, the mechanism of inflammation arises from a defect in recognition of normal 
commensal bacteria by the intestinal immune system.
8 
Pattern recognition receptors (PRR) on 
the mucosal epithelium such as toll-like receptors or the APCs that have mutated, lead to the 
“misguided” recognition of commensal bacteria as potential pathogens.3,8  This 
misrepresentation induces T cell differentiation and the production of robust quantities of  
pro-inflammatory cytokines and a subsequent influx of mucosal inflammatory cells.
7
 The 
most common pathologic type of IBD in both dogs and cats is lymphoplasmacytic enteritis.
2,3 
Obtaining biopsies in dogs with IBD is paramount to making a correct diagnosis. 
Intestinal biopsies may be obtained using surgical or endoscopic techniques. There are 
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guidelines established by the World Small Animal Veterinary Association Gastrointestinal 
Standardization Group to help veterinarians diagnose and characterize the histopathological 
GI mucosal changes in dogs and cats with GI disease.
7 
The histopathologic evaluation of the 
biopsies obtained is paramount for an accurate diagnosis of IBD.  Cell type infiltration of the 
lamina propria aids in clinical decision making. For instance, the presence of macrophages 
and neutrophils may suggest a potentially infectious pathogen, versus infiltration of 
eosinophils, suggesting a parasitic cause or response to dietary constituents.
7  
Therapies for IBD are influenced by the histopathology of the GI biopsies and the 
severity of the clinical signs. The goal of therapy largely involves ameliorating the clinical 
(GI) signs.
2,3,7
 Empirical treatment with a highly digestible novel protein diet should be 
performed first. Typically, a novel protein diet is suggested for dogs with chronic 
enteropathies; some examples of novel proteins available as canine diets include bison, 
kangaroo, duck, salmon, and venison. Many commercially available dog foods have a mix of 
proteins which provides a potential for exposure to numerous dietary antigens.
5,7 
 Some of the 
proposed dietary antigens present in commercial dog foods include soy, beef, gluten, lactose, 
and wheat. Currently, several major dog food companies have developed hydrolyzed protein 
diets that are suggested to be “hypoallergenic”.3,5 The hydrolytic process reduces the native 
protein to a size that is theorized to be less likely to stimulate the immune system.
5
  Individual 
response to diet trials varies between dogs.  A diet trial should be done for at least 2-4 weeks 
to see if there is a favorable response.
3 
There have been many studies that have shown 
improvement of clinical signs in up to 50% of dogs with chronic enteropathies.
7 
Empiric therapy for protozoa such as Giardia and other endoparasites is commonly 
prescribed by clinicians for dogs with chronic enteropathies. Typically, the anti-parasitics 
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fenbendazole and pyrantel pamoate are considered standard choices for dogs presenting with 
gastrointestinal disease.
3,7 
A 28 day trial of antibiotics such as metronidazole and tylosin can 
also be used empirically to rule out ARD.
3,7 
 If the clinical signs recur after discontinuing the 
antibiotic, then long-term antibiotic therapy can be continued.
7 
If the response to these 
empiric/trial therapies are incomplete or poor, or if there is moderate to severe evidence of 
inflammation on histopathology, further treatment options should be considered.
3 
Since IBD 
is the result of mucosal immune dysregulation, oral immunosuppressive therapy to alleviate 
the offending clinical sign is warranted.  Some common immunosuppressive agents include 
prednisone, budesonide, and cyclosporine, among others. 
3,7
 Dosing of these medications are 
slowly tapered over weeks to months to ameliorate the offending clinical signs using the 
lowest effective dose. 
IBD in humans describes a group of inflammatory GI disorders including Crohn’s 
disease (CD) and ulcerative colitis (UC) that induce an immune mediated inflammation 
within the mucosa of the gastrointestinal tract (but predominantly the colon and rectum).
9,10
  
This inflammation induced by noxious substances in the lumen stimulates local production of 
TNF-a, IL-6 and IL-1b.
8,9,11,
 Histopathology of the mucosa is paramount in diagnosing 
disorders of the gastrointestinal tract, as IBD is arbitrarily characterized by the type of 
inflammatory infiltrate present.
10,12
 Intestinal mucosal samples can be obtained via surgical 
intervention, or less invasively, by endoscopy. 
Gastrointestinal endoscopy is commonly utilized in human and veterinary medicine as 
a relatively non-invasive diagnostic tool for the identification, assessment, and localization of 
disease in the gastrointestinal tract.
13-15 
 Endoscopy allows human and veterinary physicians a 
means to obtain histopathologic samples to further evaluate and characterize disease in their 
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patients as well as response to treatment interventions.
15,16
  However, in veterinary medicine, 
few studies have examined and correlated histopathology and clinical signs.
10
  In addition, it 
is well recognized that variation of lesion interpretation exists among endoscopists and 
pathologists in both the human and veterinary literature.
10,13,17,18 
In human medicine, development of multiple standardized disease indices and activity 
scores to define inflammatory activity for CD and UC have been proposed and validated.
15,19
   
The purpose of these activity scores and indices has been to unify gastroenterologists’ 
endoscopic lesion description and to characterize severity.
15,19,20
  Human physicians have tried 
to provide an objective and reliable way to assess endoscopic lesions for patient disease 
monitoring and continuity of care between attending clinicans.
15  
There is very little veterinary literature available that examines endoscopic mucosal 
lesions and the consistency of mucosal interpretation among endoscopists.  There have not 
been any published studies that have assessed inter-observer agreement between veterinary 
endoscopists when evaluating mucosal lesions. The goal of the following thesis is to further 
describe the importance of gross endoscopic disease description, evaluate groups of 
endoscopists’ interpretations of endoscopic lesions, and suggest a simplified mucosal 
endoscopic index to implement when evaluating dogs with IBD. 
 
Thesis Formatting 
The following Master of Science thesis is arranged in a journal paper format.  The 
references utilized for each chapter are listed at the end of each chapter.  Chapter 1 begins 
with a general introduction to the thesis including a background of canine IBD and a 
description of human mucosal inflammation/lesion indices. Immediately following chapter 2, 
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the literature review, I have included two papers that either have been submitted to peer 
reviewed journals as novel and individual manuscripts, or are in preparation for submission.  
Chapter 5 of the thesis summarizes the overall concept of the research hypothesis, results, and 
areas for further research.  
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CHAPTER 2 
LITERATURE REVIEW: 
Human endoscopic indices 
 Most gastroenterologists agree that Dr. Sidney Truelove is the founding father of IBD 
therapy.  He recognized in the early 1950s that just evaluating symptoms of the patient was an 
inadequate means of measuring treatment efficacy, and a more objective measure of disease 
activity was necessary.
1 In the decade following Dr. Truelove’s studies and observations 
regarding IBD, Dr. Baron critically evaluated endoscopic scoring of lesions.
1-3 
Dr. Baron 
emphasized the importance of visual mucosal interpretation in IBD patients; however, the 
appearances of the diverse lesions can be difficult to describe without clearly defined terms.
2  
Dr. Baron emphasized the necessity of evaluating those mucosal characteristics that could be 
consistently reported by various observers.
1,2 
He placed more emphasis on the presence or 
absence of clearly defined mucosal features and thought that criteria with descriptive terms 
regarding shades of color and texture were less reliable.
2 
Initially, human mucosal 
assessments could only be made to the locations limited by rigid sigmoidoscopy.
1 
 Through 
the years improvements have been made in endoscope technology and comfort. 
3 
Today, we 
currently have the advantage of flexible and capsule endoscopes with high definition 
visualization capabilities to fully evaluate mucosal surfaces, but there is still no unified human 
measurement of mucosal endoscopic activity.
1,3
   
 In humans, the two most commonly recognized and well-described inflammatory 
bowel disorders are Crohn’s disease (CD) and Ulcerative colitis (UC).  It is well known 
among physicians that a definitive cause for the underlying inflammatory condition has not 
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been identified, and that therapy has largely been focused on ameliorating clinical signs.
4-6 
These diseases are notorious for relapse and characterized by abdominal pain, diarrhea and 
even bleeding.
5 
  Monitoring therapy and identifying whether patients are relapsing or are in 
remission are integral components of patient management.   
 Although various non-invasive methods of intestinal disease measurement have been 
developed, there is a lack of specificity.
5,6,11 
 Serologic and fecal markers such as C-reactive 
protein and calprotectin have been utilized, but further studies need to be performed to 
solidify their use in disease diagnosis and monitoring. 
5,6,11 
The most common way to monitor 
disease progression/healing of lesions is via direct mucosal evaluation.  This is done largely 
with gross endoscopic mucosal evaluation in combination with histological examination.
3,5   
High quality images of the mucosal surface are a means to critically evaluate lesions and 
allow review by experts without a bias of current treatment for assessment.
1 
Limitations that 
can affect mucosal interpretation include the preparation of the bowel, the equipment used, 
and the experience and training of the endoscopist on lesion identification.
3,5,6 
  
The reliability of the individual endoscopist’s mucosal interpretation and assessment 
has been questioned.
7-11
   In addition, there have been numerous debates regarding lesion 
identification between endoscopists with varying training levels.
7-11 
As a result, multiple 
endoscopic grades and indices have been developed and validated.  For instance, there are 
several activity indices in use when describing patients with UC, such as Truelove, Baron, 
Blackstone, and the modified 6-point activity index.
2,4,7,11
 Most of these indices prioritize 
several key features in the lesions assessed including; friability, granularity, ulcers, erythema, 
and mucosal vascular patterns.
2,4,7,11 
 There are independent variables and scoring dependent 
upon which individual index is used.  As already mentioned, the Baron index minimizes the 
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importance of lesion identification for features that cannot be clearly defined and rely on 
individual subjective interpretation such as color changes (erythema) or texture of the 
mucosal surface (granularity).
2  
This is in contrast to some of the other indices such as the 
Blackstone and modified 6-point scale that readily describe and even quantitate these types of 
lesions.
4  
In regards to CD, there are also many disease activity indices currently in use.  The 
two most common are the Crohn’s Disease Endoscopic Index of Severity (CDEIS) and the 
Simplified Endoscopic Activity Score for Crohn’s disease (SES-CD).8,9  The CDEIS was 
developed to report the global appraisal of lesion severity among endoscopists in a 
standardized way.
9 
The format of the CDEIS involves evaluating 5 specific colonic locations 
and describing if 4 specific pre-determined/specific lesions are present.
8,9 
 This method was 
deemed reliable, albeit time consuming, and the scores obtained were reproducible by 
multiple endoscopists.
8,9 
In response, the SES-CD was developed to provide a simplified and 
more rapid clinical mucosal assessment by defining 4 variables and using a quantitative 
system of measurement.
8 
 
Countless numbers of human endoscopic indices have been developed and utilized 
with various amounts of success since the advent of human endoscopy.
1
 There is no 
universally accepted and clearly comprehensive index for either UC or CD. The benefits of 
gastrointestinal endoscopy including disease diagnosis, monitoring treatment response, and 
disease surveillance have been widely accepted and proven in various studies.
3 
Limiting 
factors for the use of endoscopic indices are reliability of results, reproducibility of lesion 
assessment, simplicity of the score, experience of the endoscopist, and availability of mucosa 
for assessment.
4,7-11 
 Based on all the scoring systems that have been evaluated, most agree 
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that clearly defined terminology of specific lesions such as friability, ulcers, and granularity 
should be noted, as well as the extent/size of the mucosal lesion.
2,5,11
 Most evaluation and 
validation of endoscopic indices agree that operator experience matters in regards to lesion 
assessment.
4-11
  
Veterinary endoscopic indices 
 The degree and severity of inflammatory bowel disease in veterinary patients is 
similar to that of humans.
12
 In comparison to the human literature, there are only a handful of 
studies that highlight or even quantify a mucosal endoscopic index.  In fact, scoring indices 
for inflammatory bowel disease in veterinary medicine were not in use until the development 
of the Canine Inflammatory Bowel Disease Activity Index (CIBDAI).
13 
This is a clinical 
index developed to summate 6 variables with quantitative scores from 0-3 to describe mild, 
moderate, or severe IBD.
13 
There are currently no universally accepted endoscopic scoring 
indices although several methods for disease descriptions have been proposed in individual 
studies recently published. 
 In 2007, Allenspach and colleagues described risk factors for dogs diagnosed with 
chronic enteropathies.  Seventy dogs were evaluated using activity indices CIBDAI and the 
Canine Chronic Enteropathy Activity Index (CCECAI), and these were compared to their 
endoscopic and histologic scores.
14 
An independent duodenal and colonic endoscopy score 
was developed for this prospective study that included a grading system from 0-3.
14 
The 
variables assessed were friability, erythema, white speckling, ulcers, cobblestone appearance, 
and difficulty insufflating the bowel during endoscopy.
14 
None of the variables were 
individual assessments, but rather a combination, as stated in the paper.  There was no 
correlation of the endoscopy score to the disease activity indices, although a grade 3 duodenal 
13 
 
endoscopy score was associated with a negative outcome.
14
 This study did not develop a 
detailed and specific mucosal endoscopic index, nor did it find major correlations with other 
disease indices. 
 Also in 2007, Garcia-Sancho and colleagues published a prospective study evaluating 
clinical, macroscopic and histopathologic assessments of dogs with nonproteinemic 
lymphocytic-plasmacytic enteritis (LPE).  Macroscopic variables were evaluated in the 
stomach and duodenum of the study dogs consisting of erosions, erythema, granularity, 
presence or absence of bile, lack of elasticity, and friability.
15
 The variables were rated in 
severity from 0-3 and for presence or absence of gross lesions.
15 
In all study dogs with LPE, 
there were macroscopic lesions, and 75% of the animals post-treatment displayed 
macroscopic improvement.
15 
In contrast to the Allenspach et al study
14
, this paper showed 
improvements in the gross endoscopic mucosal appearance in treated dogs and highlighted the 
most common pretreatment mucosal findings in both the stomach and duodenum of dogs with 
LPE.
15 
 
Finally in 2012, Larson et al reported on the duodenal endoscopic findings and 
histopathologic confirmation of intestinal lymphangiectasia (IL) in dogs. An endoscopic 
grading scale of severity was developed based on mucosal granularity, active lymphatic 
discharge and white foci.
16
 The severity of the IL was categorized from 0-3.
16 
Based on the 
results of the study, there was poor sensitivity and specificity of the duodenal mucosal 
endoscopic appearance in predicting IL in dogs.
16
 
 These 3 veterinary studies are by no means a comprehensive list of the available 
endoscopic indices available.  Since there is no universal veterinary standard for evaluating 
the gastrointestinal mucosal surface, each study involving gastrointestinal endoscopy often 
14 
 
developed an individual scoring index.  This makes the interpretation of lesion assessment 
difficult to analyze, as there are a multitude of lesion variables assessed, discrepancies in the 
importance of severity versus presence or absence of lesions, and the ability and experience of 
the endoscopist is often not considered.  This highlights the inherent problems with 
endoscopic mucosal assessments made in dogs with various chronic enteropathies and 
emphasizes the necessity for a universal system of endoscopic mucosal assessment.  
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CHAPTER 3 
 
INTER-OBSERVER AGREEMENT IN THE DUODENAL ENDOSCOPIC ASSESSMENT 
OF CANINE INFLAMMATORY BOWEL DISEASE  
J.E. Slovak, C. Wang, J.A. Morrison, K.L. Deitz, D.N. LeVine, C. Otoni, R.R. King, L.E. 
Gerber, K.R. Hanson, A.P. Lundberg, A.E. Jergens 
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J. Slovak co-chose images/cases utilized; organized the display/construction of images, 
templates and evaluation forms; collected, graded and interpreted data. 
 
Abstract 
Background: Measures of inflammatory activity are essential in defining disease burden at 
diagnosis and for determining effects of treatment in dogs with inflammatory bowel disease 
(IBD). GI endoscopy is performed for direct inspection of the mucosa and acquisition of 
biopsies for histopathologic evaluation. Endoscopic observations might also be used to 
determine the extent and severity of the disease. 
Aim: To evaluate the inter-observer agreement in the endoscopic duodenal mucosal 
assessment in canines diagnosed with IBD. 
Methods: Thirty-five archived endoscopic images of grossly normal (n=6) and inflamed 
(n=29) duodenal mucosa were displayed to 3 expert and 5 trainee endoscopists. Each image 
was assessed independently by endoscopists for inflammatory changes using established 
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indices (i.e., hyperemia, granularity, friability, lymphatic dilatation, erosions) or interpreted as 
normal mucosa (trial 1). A repeated trial (trial 2) was administered with images re-
randomized one month later accompanied by a visual template.  
Results:  There was slight inter-observer agreement in initial lesion identification for expert 
and trainee endoscopists in trial 1 (k≤0.02, p>0.05). Inter-observer agreement improved in 
trial 2 for both expert and trainee endoscopists, (k=0.2, p>0.05) for experts and (p<0.05) for 
trainees. There was a significant (p<0.01) improvement in trainee endoscopy scores of lesions 
from trial 1 to trial 2. Regression analysis showed a significant (p<0.01) difference between 
expert versus trainee endoscopy scores in trial 1. Repeat lesion assessment aided by use of a 
visual template (trial 2) improved the overall scores of trainee endoscopists to near that of 
expert endoscopists (p=0.06). 
Conclusions: Accurate assessment of IBD disease activity from endoscopic findings 
benefitted from operator experience.  
 
Different indices have been proposed to measure the activity (and/or severity) of 
canine inflammatory bowel disease (IBD) to evaluate efficacy of treatment in clinical trials.
1-
3
All of these indices are based on clinical signs and/or biological data. Gastrointestinal (GI) 
endoscopy is a well-established technique to directly visualize the mucosa and acquire 
targeted biopsy specimens for histopathologic confirmation of intestinal inflammation. 
Because endoscopy is routinely performed for diagnosis of canine IBD, endoscopic findings 
(i.e., abnormal mucosal appearances) could be used to measure disease activity. 
 Several different endoscopic indices for evaluation of inflammatory activity in human 
IBD (i.e., Crohn’s disease [CD]4,5 and ulcerative colitis [UC]6-9) have been designed. All of 
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these scoring systems were based on the severity/extent of mucosal granularity, vascular 
pattern, vulnerability of mucosa, and/or mucosal damage (mucus, fibrin, exudates, erosions, 
and ulcers) observed during colonoscopy. However, no standardized model has been 
established. Separate studies in dogs with small intestinal IBD have yielded conflicting results 
on the utility of endoscopic scoring as a measure of disease activity.
1,10
 One potential reason 
for this discrepancy could be inter-observer variation in identifying endoscopic abnormalities 
based on operator experience and the lack of systematic endoscopic assessment. The aim of 
the present study was to evaluate the inter-observer agreement in the assessment of 
endoscopic activity in canine duodenal IBD. 
 
MATERIALS AND METHODS  
 
Selection of Images 
Two hundred archived endoscopic images from consecutive duodenoscopy procedures 
performed in dogs with IBD between 2004 and 2012 at Iowa State University were retrieved 
from a computerized database and reviewed. A total of 35 endoscopic images of normal 
(some images obtained post-biopsy) and inflamed duodenal mucosa from 25 IBD dogs were 
selected for study enrollment. Image selection was determined by joint agreement of authors 
JES and AEJ. A diagnosis of canine IBD was based on previously established 
clinicopathologic and histopathologic criteria.
1,2,10-12
 Endoscopic interpretation of intestinal 
lymphangiectasia included observation of multifocal to diffuse white foci within the mucosa 
suggestive of lymphatic distension.
15
 Duodenoscopy procedures were performed using a 
commercial video endoscope (Olympus GIF-160, Olympus Optical, Tokyo, Japan) with still 
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images of normal and abnormal mucosa captured by the endoscopist. The file size of the 
downloaded images was approximately 100 kb, with a pixel array of 640 x 480 and 24-bit 
color. These still images were then arranged in a Powerpoint
a 
presentation for testing 
purposes. 
 
Assessment of Images 
 Endoscopic still images in Powerpoint
a 
format were assessed by 3 expert and 5 trainee 
endoscopists for inflammatory activity. Expert endoscopists were defined as individuals with 
advanced clinical training and active operator participation in GI endoscopy over the 
preceding 24 months. The experts were experienced and familiar with mucosal lesions of 
disease activity as identified with GI endoscopy. Trainee endoscopists had minimal 
endoscopic training and lacked consistent endoscopic operator experience over the same 24 
month period.  
 Images were randomized by means of a Research report randomizer
b
 program and 
assessed independently by each endoscopist for inflammatory changes as originally 
determined by JES and AEJ. Neither the clinical data nor the date on which the image was 
taken was made available to the endoscopists. The endoscopic variables evaluated included 
hyperemia, erosions, granularity, friability, lymphatic dilation, or the mucosal appearance was 
interpreted as normal (Table 1). Written definitions of each variable were made available to 
all endoscopists. If an individual image contained more than one mucosal abnormality, the 
endoscopist was asked to identify the salient lesion (trial 1). The assessment of mucosal 
inflammatory changes was repeated 1 month after the first assessment (trial 2), although the 
endoscopists were not informed that they were going to assess the same images (order re-
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randomized) a second time. Additionally, each endoscopist was instructed to review a 
template of representative mucosal lesions (Figure 1) before image re-assessment (trial 2) to 
see whether this exercise improved endoscopy scores.  
 
Analysis of Data 
 Data was collected from each operator using pre-designed Excel
c
 spread sheets for 
statistical analysis. Fleiss Kappa coefficients were calculated to assess agreement among 
multiple raters within expert and trainee groups and tested against null value 0 using the “irr” 
package in R.
d
 A mixed effects logistic regression model was used to analyze endoscopy 
score agreement with gold standard for comparison of assessment accuracy using the 
Glimmix procedure in SAS. Group (trainee vs expert), trial and their interaction were the 
fixed effects in model, whereas endoscopist was the random effect. A p value < 0.05 was 
considered statistically significant.  
 
RESULTS 
    The base-line clinicopathologic characteristics in IBD dogs were similar to previous 
reports.
1,2,10-12
 The affected dogs were predominantly middle-aged (age range 1-11 years), 
exhibited chronic gastrointestinal signs, and had variable disease activity as evidenced by 
clinical scores (Table 2). There were 11 spayed females and 14 neutered males included in the 
study. Dogs with IBD included the following pedigrees: 4 West Highland White Terriers, 3 
Golden Retrievers, 2 mixed breed dogs, 2 Boxers, 2 Labrador Retrievers, 2 Shih Tzus, 2 
Yorkshire Terriers and 1 each of Wheaton Terrier, German Shepherd Dog, Viszla, English 
Bulldog, Cocker Spaniel, Gordon Setter, Beagle, and Miniature Poodle. None of the dogs had 
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evidence of extra-alimentary tract inflammation (based on results obtained from diagnostic 
testing), and each dog had failed to respond fully to previous dietary and antibiotic 
interventions. 
Among the 35 images of the test set obtained during duodenoscopic examination in 
IBD dogs, 6 were of normal mucosa (some images obtained post-biopsy), 6 showed friability, 
5 showed hyperemia, 6 showed increased granularity, 7 showed erosions, and 5 showed 
lymphatic dilation.  
Based on Fleiss Kappa statistics evaluation, the inter-observer agreement within expert 
and trainee groups improved among experts from trial 1 k<0.01, p>0.05, to trial 2 k=0.2, 
p>0.05 and among trainees from trial 1 k=0.02, p>0.05 to trial 2 k=0.2, p<0.05. Using the 
Glimmix procedure, showing comparison within the groups, there was a significant (p<0.01) 
improvement (17.1%) in the trainee endoscopists regarding lesion assessment from trial 1 to 
trial 2.  The expert endoscopists showed no statistical significant improvement between trial 1 
and trial 2 (p=0.19), although there was a 7.6% improvement. Regression analysis showed a 
significant (p<0.01) difference between operator groups regarding trial 1 lesion assessment. 
Repeat duodenal image evaluation aided by use of a visual template, (trial 2) improved the 
overall scores of trainee endoscopists to near that of expert endoscopists, (p=0.06).  
 
DISCUSSION  
The results of this study indicate that operator experience matters when making 
endoscopic mucosal assessments. Operator experience may be gained from performing 
numerous endoscopic procedures and/or the provision of a written/pictorial template to aide 
identification of mucosal lesions.  
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Gastrointestinal endoscopy is an important tool in the diagnosis of canine IBD. 
Gastroscopy, enteroscopy, and colonoscopy are of value in the assessment of specific organ 
involvement in IBD and to differentiate IBD from other causes of chronic enteropathy. Recent 
advances in patient preparation and instrumentation,
14,16,17
 mucosal examination 
techniques,
13,18
 and the development of forceps biopsy standards
19-20 
have made GI endoscopy 
the preferred method for diagnosis of small and large intestinal inflammation.   
Canine IBD is often characterized by a relapsing and remitting clinical course. 
Determination of inflammatory activity is important for assessing disease severity and for 
tailoring patient therapy. Different indices for assessment of disease activity have been 
proposed. Clinical indices utilize scoring systems derived from GI signs alone (CIBDAI)
2
 or 
in combination with laboratory testing (CCECAI)
1
 to quantify intestinal inflammation. 
Noninvasive serologic markers including perinuclear anti-neutrophil cytoplasmic antibodies 
(pANCA)
21-23
 and C-reactive protein (CRP)
2,3,24
 may provide only indirect assessment of 
disease activity. Histopathological examination, while required for diagnosis of IBD, is 
hindered by poorly standardized grading criteria and disagreement among pathologists in 
defining mucosal inflammation.
25,26
 
Since endoscopy provides immediate and direct assessment of intestinal mucosal 
damage, endoscopic findings might be used to measure inflammatory activity. Several 
endoscopic activity indices for CD
4,5 
and UC
6-9 
are in use. Salient lesions of human IBD (ie, 
CD and UC) range from erythema, loss of vascularity, friability, and granularity of the 
mucosa to erosions/ulceration. Similar endoscopic indices have been used in canine IBD 
including erythema, friability, erosions/ulceration, cobble-stone appearance (granularity), 
white speckling on the surface, and difficulty in insufflating (stenosis).
1,10,11
 Clinical trials 
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utilizing endoscopic scoring for canine IBD are limited and have provided conflicting results 
on the utility of endoscopic scoring as a measure of disease activity.
1,10
 A reason for this 
discrepancy could be inter-observer variation in identifying endoscopic abnormalities based 
on operator experience and the lack of systematic endoscopic assessment.   
This study investigated inter-observer agreement in the assessment of endoscopic 
activity in IBD dogs using defined descriptors of mucosal inflammation. Both written 
descriptions and a visual template of mucosal lesions were used to assess the role of operator 
experience in defining duodenal endoscopic activity in dogs. Our results indicated that there 
was slight to fair inter-observer group agreement in lesion identification in expert and trainee 
endoscopists for either trial 1 or trial 2. However, there was significant inter-observer 
difference in lesion assessment when still images of IBD were evaluated by the 3 experienced 
versus 5 trainee endoscopists in trial 1. Analysis of inter-observer agreement showed a 
significant difference between operator groups regarding lesion assessment with expert 
endoscopists having less chance of disagreement regarding the identification of endoscopic 
abnormalities. This observation of improved inter-observer agreement of experienced versus 
trainee endoscopists emphasizes the value of operator experience and is similar to results in 
humans with IBD.
8,27
 
Allenspach et al. previously evaluated the association between endoscopic scores of 
the duodenum and colon with other inflammatory indices (ie, clinical activity [CIBDAI] and 
histopathology) as partial assessment of long-term outcome in dogs with chronic 
enteropathies.
1
 In this study, numerical scores (range 0-3; normal to severe mucosal 
inflammation) were assigned by one of 2 operators using mucosal assessment criteria of 
erythema, friability, white speckling, granularity, and luminal stenosis. No correlation was 
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found between endoscopy scores and histology scores pre- versus post-treatment; however, an 
endoscopy score of 3 in the duodenum, indicative of severe inflammation, was significantly 
associated with negative outcome. In a separate study, Garcia-Sancho et al. performed 
endoscopic examination in 16 dogs diagnosed with lymphocytic-plasmacytic enteritis and 
evaluated gastric/duodenal lesions of mucosal erythema, granularity, friability, erosions, and 
luminal distension before and after IBD therapy.
10
 While the number and relative experience 
of endoscopists were not noted in this report, these investigators showed significant 
differences between pre- and post-treatment macroscopic endoscopic lesions in the stomach 
and duodenum.  
Our choice of endoscopic mucosal characteristics (ie, hyperemia, friability, 
granularity, erosions, and lymphatic dilatation) to evaluate was based on the personal 
experiences of AEJ in performance of duodenoscopic procedures over many years. We have 
observed that observer variation for graded characteristics (i.e., mucosal hyperemia – is it 
pale, pink, or red?) is quite high, while that for discontinuous variables (i.e., presence or 
absence of erosions) is generally low.
7
 More importantly, we have also observed that operator 
experience plays an important role in endoscopic assessment with trainee endoscopists more 
likely to miss mucosal lesions or misinterpret normal versus abnormal mucosa. The results of 
this study would confirm these previous anecdotal observations. While hyperemia and 
luminal distensibility have been used in previous endoscopic indices for dogs, we have not 
found them useful in the past or in the current study.
1,10
 In fact, of the endoscopic variables 
evaluated across a spectrum of GI organs (i.e., stomach, small intestine, and colon) we found 
mucosal hyperemia to have the greatest variability amongst all observers, including 
experienced endoscopists (JES and AEJ, unpublished observations). 
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With regards to statistical analysis, the use of the Fleiss Kappa coeffcients were 
calculated to assess agreement among multiple observers versus Cohen’s kappa which 
compares inter-observer agreement between 2 observers.  Although the kappa scores within 
the expert and trainee groups for trial 1 showed only slight agreement, they both improved to 
fair agreement for both groups in trial 2.  The p value for the experts in both trials were 
greater than 0.05 and could have been the result of a Type II error.  However, the trainee’s p 
value in trial 2 was less than 0.05, which is unlikely to have occurred by chance alone.  
There were several potential limitations of our study. First, we utilized a single center 
for our study and focused only on duodenal endoscopic assessment of dogs with IBD. 
Whether the same results for inter-observer variability across different study centers, 
endoscopic interpretation by non-specialist clinicians, or evaluation of other alimentary tract 
organs (i.e., stomach, ileum, and colon) in dogs having different enteropathies might yield 
similar results was not assessed. Second, we used still images of endoscopic lesions versus 
video streams to evaluate variation between operator cohorts. Our rationale was that still 
images in texts or continuing education events are routinely utilized for endoscopic training 
purposes. Additionally, a manageable number of still images could be more easily evaluated 
twice by the same clinicians in this study, which assured good compliance in spite of their 
other professional duties. Accurate assessment of UC endoscopic activity from archived still 
images has been previously reported.
8
 
In summary, a simple classification of the variable mucosal appearances in the 
duodenum of dogs with IBD is described. According to the results from this study, accurate 
assessment of IBD activity from duodenal endoscopic findings benefitted from operator 
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experience. Acceptable agreement rates can be obtained by endoscopists under training using 
well-defined endoscopic appearances.  
 
Footnotes: 
a
 Research report randomizer www.randomizer.org 
b
 Powerpoint
TM 
c 
Excel
TM 
d”irr” package in R  R Core Team, Vienna, Austria  
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Table 1: Descriptions of endoscopic variables used in the study 
Endoscopic criteria for duodenal mucosal assessment 
Hyperemia Gradations of mucosal redness (pale  red) 
Friability Mucosal bleeding on contact with endoscope or biopsy forceps 
Granularity Alteration in the texture of the mucosal surface 
Erosions Superficial linear mucosal defect(s) with hemorrhage 
Lymphatic dilatation Multifocal to diffuse white foci within the mucosa 
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Figure 1: Representative lesion images
 
Normal (A,B); Hyperemia (C,D); Friability (E,F); Lymphatic dilation (G,H);  
Granularity (I,J); Erosions (K,L)  
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Table 2: Clinical characteristics of IBD dogs 
 
Baseline characteristics of IBD dogs 
Mean age (yr.) 6.8 
Male sex, n (%) 14 (56) 
Disease duration (mo.) 4.8 
CIBDAI score 
a
 5.9 
Endoscopic lesions 
b
 100% 
Histopathologic grade 
c
  
   Mild IBD 24% 
   Moderate-severe IBD 76% 
 
a
 Mean disease activity at diagnosis; range 0 – 18 
b
 Mucosal lesions of friability, granularity, or erosions 
c
 Predominant lymphocytic-plasmacytic inflammation 
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CHAPTER 4 
 
DEVELOPMENT AND VALIDATION OF A NOVEL ENDOSCOPIC SCORING INDEX 
FOR CANINE INFLAMMATORY BOWEL DISEASE  
J.E. Slovak, C. Wang, Y. Sun, C. Otoni, J. Morrison, K. Deitz, D. LeVine, A.E. Jergens 
*In preparation for submission to the Journal of Veterinary Internal Medicine 
J. Slovak co-chose images/cases utilized; organized the display/construction of images, 
templates and evaluation forms; collected, graded and interpreted data. 
 
Abstract 
Background: Endoscopy is the gold standard to evaluate dogs with IBD, but the reliability of 
the assessment of endoscopic lesions is unclear.  Previous studies have provided conflicting 
results as to the benefit of endoscopic activity in the diagnosis and management of canine 
intestinal disease. Moreover, mucosal criteria have varied between trials, which may create 
confusion and confound accurate interpretation between endoscopists.   
Aim: The aim of this study was to develop and validate a mucosal endoscopic index for 
assessing the severity of lesions in dogs with inflammatory bowel disease. 
Methods: In total, 95 images of inflammatory and normal mucosa from dogs with chronic 
enteropathies were displayed to 3 expert and 5 trainee endoscopists (initial test). Each picture 
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was assessed independently by the endoscopist for inflammatory changes, using established 
indices or interpreted as normal mucosa from multiple areas of the GI tract (i.e., stomach, 
duodenum, and colon).  Agreement was measured between the trainee and expert 
endoscopists for each organ.  The results of the duodenal assessments have been reported in a 
previous study. The developed index was then applied to a prospective independent group of 
dogs (23 total) diagnosed with inflammatory bowel disease for a validation study. 
Comparisons were made between 2 expert endoscopists (JES & AEJ) to measure mucosal 
assessment agreement. 
Results:  There was only slight agreement among the experts when evaluating the stomach 
k=0.04. There was fair agreement among the trainees evaluating the stomach k=0.2 and fair 
agreement for both the trainees and experts when evaluating the colon k=0.2. For the 
validation study, the expert endoscopists had substantial to almost perfect agreement for each 
lesion assessed and for the total score in the stomach (k> 0.8), had moderate to substantial 
agreement assessing the small intestine (k>0.6-0.84), and substantial agreement when 
assessing the colon (k>0.7-1). 
Conclusions: Trained operators can identify and agree upon most endoscopic lesions of 
mucosal inflammation. 
Introduction 
 Inflammatory bowel disease is one of the most important differential diagnoses in 
dogs with chronic enteropathies.
1-4 
Additional causes include antibiotic responsive diarrhea 
(ARD) and diet responsive diarrhea (DRD).
1-4  
The diagnosis of IBD relies heavily on clinical 
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signs, response to therapy, serologic and fecal testing, abdominal imaging, and 
gastrointestinal endoscopy.
4-8  
 
Gastrointestinal endoscopy provides an immediate method for assessing intestinal 
mucosal damage. Endoscopy is considered the gold standard to evaluate and obtain biopsies 
from dogs with IBD, but the reliability of mucosal lesion assessment is unclear.
6,9-13 
There is a 
paucity of published veterinary literature regarding mucosal assessment in dogs with chronic 
enteropathies.
3,9-10 
In human medicine, the most commonly recognized endoscopic mucosal 
indices are those established for ulcerative colitis (UC) and Crohn’s disease (CD). 6,12-18 There 
is little agreement in the human literature as to which index is superior for evaluation, 
although most agree that an ideal endoscopic index should have high concordance between 
endoscopists and high reproducibility regardless of the endoscopist’s experience.14,16 
 
Previously published veterinary studies have failed to determine whether standardized 
endoscopic evaluation is useful in defining the severity and extent of inflammatory lesions in 
affected dogs.  Former veterinary clinical trials have used multiple individual endoscopic 
indices in order to classify mucosal variables for each individual study.
3,9-10 
 The aim of the 
present study is to develop and validate an endoscopic index for mucosal assessment in dogs 
with inflammatory bowel disease.
  
 
MATERIALS AND METHODS 
Selection of Images (initial test) 
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 Archived endoscopic images from gastrointestinal (GI) endoscopic procedures 
performed at Iowa State University from 2002-2012 were retrieved from a computerized 
database and reviewed.  A total of 30 stomach endoscopic images from 27 dogs, 35 duodenal 
images from 25 dogs, and 30 colonic images from 23 dogs were selected for study enrollment.  
Image selection was determined by joint agreement of authors JES and AEJ.  Endoscopic 
procedures were performed using a commercial video endoscope (Olympus GIF-160, 
Olympus Optical, Tokyo, Japan) with still images of normal and abnormal mucosa captured 
by the endoscopist.  The file size of the downloaded image was approximately 100 kb with a 
pixel array of 640 x 480 and 24-bit color.  These still images were then arranged in a 
Powerpoint
a
 presentation for testing purposes. 
Assessment of Images (initial test) 
 Still endoscopic images in Powerpoint
a 
format were assessed by 3 expert and 5 trainee 
endoscopists for inflammatory activity (hyperemia, granularity, friability, lymphatic 
dilatation, erosion) or interpreted as normal mucosa. Expert endoscopists were defined as 
individuals with advanced clinical training and active operator participation in GI endoscopy 
over the preceding 24 months. The trainee endoscopists had either minimal endoscopic 
training and/or lacked consistent endoscopic operator experience over the same 24 month 
period. 
 Images of each organ were randomized by means of a Research report randomizer
b 
program and assessed independently by each endoscopist.  No clinical data or the date on 
which the image was taken was made available to the endoscopists.  The endoscopic variables 
evaluated for the stomach included; granularity (6), friability (6), erosions (8), hyperemia (3), 
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normal mucosa (3) and normal post-biopsy mucosa (4), for the small intestine (previously 
reported); granularity (6), friability (6), erosions (7), lymphatic dilation (5), hyperemia (5), 
normal mucosa (4), normal post-biopsy mucosa (2), and for the colon; granularity (7), 
friability (6), erosions (7), mass (2), normal mucosa (5), and normal post-biopsy mucosa (3). 
Written definitions of each variable were made available to all endoscopists.  If an individual 
image contained more than one mucosal abnormality, the endoscopist was asked to identify 
the dominant lesion. 
Selection of Images (validation test) 
 Selected endoscopic video clips of a prospective group of 23 dogs diagnosed with 
inflammatory bowel disease at Iowa State University from 2011-2013 were reviewed from a 
computerized disc of the previously performed GI procedures.  All 23 dogs had an upper GI 
endoscopy performed, and 10 of those dogs had a concurrent colonoscopy made available for 
review. All endoscopic procedures were performed using the same equipment. 
Assessment of Endoscopic Video (validation test) 
 Video was recorded for each endoscopic procedure on the endoscopy computer hard 
drive and a separate compact disc for the prospective group of 23 IBD dogs. Approximately 5 
minute representative video clips of the endoscopic procedure including mucosal biopsies 
were viewed for each organ (stomach, duodenum, and colon) by 2 expert endoscopists (JES & 
AEJ).  Answers were recorded using a 0-2 point system (0=absent, 1=mild-moderate, 
2=moderate-severe) for the following variables for each organ; stomach (max total 6 pts); 
granularity, friability, erosions, duodenum (max total 8 pts); granularity, friability, erosions, 
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and lymphatic dilation, and the colon (max total 6 pts); granularity, friability, erosions. 
(Figure 1) 
 
 
Analysis of Data (initial test)  
 Data was collected from each operator (3 expert and 5 trainee) using pre-designed 
Excel
c 
spread sheets for statistical calculation. Fleiss Kappa coefficients were used to measure 
agreement within the expert and trainee groups. Additional analysis was performed using the 
Glimmix procedure.  A mixed logistics regression model used mean values to compare inter-
observer agreement between trainee and expert endoscopists.  A p value <0.05 was 
considered statistically significant. 
Analysis of Data (validation test) 
 Data from both expert endoscopists were recorded using a 0-2 point assessment for 
statistical calculation. Agreement between the two endoscopists were assessed using Cohen’s 
kappa coefficient for each score and each organ.  Additionally, agreement between the two 
endoscopists was also assessed using a lesion present (1) or absent score (0). The difference in 
the distribution of the scores between the endoscopists was assessed using the test of 
symmetry.  
Results (initial test) 
 Thirty endoscopic stomach images were obtained from 27 dogs.  The dogs’ ages 
ranged from 1-13 years with a mean of 8 years.  There were 14 spayed females, 8 neutered 
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males, 4 intact males, and 1 intact female included with the following pedigrees: 2 
Weimaraners, 2 American Eskimos, 2 mixed breed, 2 Vizslas, 2 Labrador Retrievers, 2 West 
Highland White Terriers, and 1 each of Pomeranian, Bernese Mountain Dog, Wheaten 
Terrier, Sheltie, Chow Chow, Shar Pei, Pembroke Welsh Corgi, English Bulldog, Cavalier 
King Charles Spaniel, Basset Hound, Samoyed, Boston Terrier, Miniature Schnauzer, Gordon 
Setter, and an Akita.  All dogs exhibited chronic gastrointestinal signs. Fleiss Kappa statistics 
performed testing for agreement among the experts was k=0.04 and k=0.15 for the trainees. 
There was no significant difference when comparing the expert to the trainee group (p=0.10). 
 As previously reported, 35 duodenal endoscopic images were obtained from 25 dogs 
ranging in age from 1-11 years (mean 6.8 years).   There were 11 spayed females and 14 
neutered males included in the study.  The following breeds were represented 4 West 
Highland White Terriers, 3 Golden Retrievers, 2 mixed breed dogs, 2 Boxers, 2 Labrador 
Retrievers, 2 Shih Tzus, 2 Yorkshire Terriers and 1 each; Wheaton Terrier, German Shepherd 
Dog, Vizsla, English Bulldog, Cocker Spaniel, Gordon Setter, Beagle, and a Miniature 
Poodle. Fleiss Kappa statistics performed testing for agreement among the experts was 
k=0.01< and k=0.02 for the trainees. There was a significant difference when comparing the 
experts to the trainees for duodenal evaluation (p=0.05). 
 Thirty colonic endoscopic images were obtained from 23 dogs ranging in age from 1-
11 years (mean 6.8 years).  There were 11 spayed females, 11 neutered males, and 1 intact 
male included in the study.  The represented breeds were as follows; 4 Boxers, 3 Shih Tzus, 2 
German Short Haired Pointers, 2 Labrador Retrievers, and 1 each of the following; West 
Highland White Terrier, Miniature Dachshund, Brittany Spaniel, Basset Hound, mixed breed, 
Weimaraner, German Wire Haired Pointer, Australian Shepherd, Rottweiler, Siberian Husky, 
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Beagle, Pembroke Welsh Corgi, and a Bichon Frise.  Fleiss kappa statistics performed testing 
for agreement among the experts was k=0.22, and k=0.15 for the trainees. There was no 
significant difference when comparing the expert to the trainee group (p=1). 
 
Results (validation test) 
 Twenty-three dogs with histopathologic confirmed inflammatory bowel disease were 
prospectively enrolled in a study.  Their ages ranged from 1-14 years (mean 6.7 years).  There 
were 14 spayed females, 8 neutered males, and 1 intact male included for evaluation.  Their 
pedigrees were as follows; 4 West Highland White Terriers, 3 mixed breeds, 2 Shih Tzus, 2 
German Shepherd Dogs, 2 Labrador Retrievers, 2 Boxers, and 1 each of the following; 1 
German Short Haired Pointer, 1 Gordon Setter, 1 Boston Terrier, 1 Scottish Terrier, 1 Vizsla, 
and 1 Collie.  All 23 dogs had stomach and duodenal evaluations performed, and 10 of these 
dogs also had a colonoscopy performed. 
Comparisons were made between 2 expert endoscopists when making mucosal 
evaluations by watching 5 minute representative video clips of the stomach, duodenum, and 
colon. For the quantitative scoring system (0-2), there was almost perfect agreement when 
comparing total scores of the stomach assessment for each patient between expert 
endoscopists (weighted k=0.87).  There was moderate agreement in total duodenal mucosal 
assessment between expert endoscopists (weighted k=0.6), and there was substantial 
agreement between expert endoscopists when making colonic mucosal assessments (weighted 
kappa=0.74).  (Table 1) 
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When assessing individual variables for each organ, there was substantial agreement 
between the expert endoscopists when grading the stomach (erosion: k=0.84, granularity: k=1, 
friability: k=0.8).  The small intestine showed moderate agreement between the expert 
endoscopists when assessing mucosal lesions (erosion: k=0.84, granularity: k=0.66, friability: 
k=0.67, lymphatic dilation: k=0.62), and the colon assessments showed substantial agreement 
between expert endoscopists (erosion: k=1, granularity: k=1, friability: k=1).  
Similarly, for the qualitative comparison of a lesion being present or absent, there was 
almost perfect agreement when comparing total scores of the stomach assessment for each 
patient between expert endoscopists (weighted k=0.87).  There was moderate agreement in 
total duodenal mucosal assessment between expert endoscopists (weighted k=0.58), and there 
was substantial agreement between expert endoscopists when making colonic mucosal 
assessments (weighted k=0.8). (Table 2) 
Discussion 
 Canine inflammatory bowel disease is a major component in dogs with chronic 
enteropathies.  Evaluation of endoscopic mucosal surfaces of dogs with IBD is routinely done 
during the diagnostic process. As a result, mucosal disease is an important measurement in 
identifying disease and monitoring treatment in dogs with IBD.  There is a need for a simple, 
reproducible, and validated veterinary scoring index. To date, there have been no veterinary 
studies proposing and validating a canine endoscopic mucosal scoring index.  This paper 
proposes a simplified endoscopic mucosal index and applies the index to a prospectively 
enrolled group of dogs with IBD to compare agreement between experienced endoscopists.  
Our results indicate that there is little difference within and among groups of trainee and 
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expert endoscopists when assessing mucosal lesions, and there is moderate to substantial 
agreement between endoscopists when evaluating mucosal lesions in dogs with IBD. 
 In human medicine, multiple indices have been proposed to assess and quantify 
mucosal damage, especially in relation to UC and CD.
12-18  
In fact the first endoscopic 
mucosal assessments and scores were made by Sidney Truelove in 1955, known as the 
founding father of human IBD therapeutics.
13,14,19  
Since then, several human indices have 
been proposed to measure the disease activity and severity of both CD and UC.
12-18 
 At 
present, many human gastroenterologists utilize the Ulcerative Colitis Colonoscopic Index of 
Severity (UCCIS) and the Simplified Endoscopic Activity Score for Crohn’s Disease (SES-
DC).
16,18 
 
In veterinary medicine, the diagnosis of canine IBD is the result of excluding 
metabolic, infectious, neoplastic, or obstructive disorders of the gastrointestinal system.
3,4,20  
Determining endoscopic inflammatory activity is crucial for the assessment of disease and for 
tailoring appropriate therapy.
3,4 
 However, there is a wide variation among endoscopists in the 
mucosal assessment of disease.
21-23
 As such, there is a need for a simplified veterinary 
endoscopic scoring index. 
 In our study, the mucosal lesions chosen for assessment were based on former 
veterinary and human indices developed for various chronic enteropathies.
3,9,10,12-18 
There was 
no significant difference within the trainee group when assessing the stomach, duodenum or 
the colon.  For the expert group, there was little agreement when assessing the stomach 
(k=0.04).  This may be due to lesion bias based on prior experiences, such as “over or under-
interpreting” lesions. When comparing the expert to the trainee endoscopy scores, there was 
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no significant difference in lesion assessment for the stomach or the colon.  As previously 
reported in chapter 3, there was a significant difference in the duodenal assessment between 
experts and trainees (p<0.01).  Again, this is likely a result of the inexperience of the trainee 
endoscopists.  Overall, the agreement rate between the expert and the trainee endoscopist 
were very good.  
 When the developed simplified endoscopic scoring index was applied to the 
prospective group of 23 dogs with IBD, there was almost perfect agreement between the 
expert endoscopists evaluating the stomach, moderate agreement when evaluating the 
duodenum, and substantial agreement with colonic evaluation.  The difference in the mucosal 
assessments could be a result of the subjective nature of scoring mild-moderate (1 pt) versus 
moderate-severe (2 pts).  However, when kappa statistics were performed comparing the 
endoscopists’ assessment of the presence of absence of a lesion, similar scores were obtained 
for the stomach, duodenum and colon. Overall, there is very good agreement between the 
endoscopists in lesion assessment. 
 There were several limitations to our study.  First, still images instead of video streams 
were used for the expert and trainee endoscopists for initial development of the scoring 
system. This was done to reduce the length of time utilized for individual mucosal 
assessment. A still image also allowed us to highlight one specific lesion.  Video streams 
would have added unnecessary length to the study as well as caused further problems with 
mucosal lesion interpretation.  Therefore, standardized archived still endoscopic images were 
included in the study. 
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 The number of expert and trainee endoscopists included in our study was low and may 
have affected our results.  We feel that having several different people with various training 
backgrounds provided variability and diversity to each endoscopy group.  A multi-
institutional study to increase the numbers of the expert and trainee groups could be pursued 
in the future to further corroborate our results. It is worthy to point out that although the 
overall number of endoscopist invited to participate in the study was low, there have been no 
other veterinary studies comparing endoscopic mucosal assessments between endoscopists.  
The three previously published canine studies regarding mucosal scoring had limited numbers 
of evaluators/endoscopists (n=2) performing the evaluation, and no reports of agreement 
between their scores.
3,9,10 
 
In summary, our simplified endoscopic activity score for canine IBD was successfully 
applied to a prospective group of dogs with histopathologically confirmed IBD.  There was 
very good agreement between the expert endoscopists evaluating their mucosal lesions in the 
stomach, duodenum, and colon using a quantitative 0-2 point scale or using a simplistic 
qualitative scale of lesion absence or presence.  Based on these results, we have determined 
that accurate mucosal endoscopic assessments between trained operators depend on detailed 
descriptions of a limited number of descriptive variables. 
Footnotes 
a
Powerpoint
TM 
b
Research report randomizer 
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Figure 1: Quantitative lesion grading scale; 0=absent, 1=mild, 2=moderate/severe 
Organ Erosion Granularity Friability Lymphatic 
dilation 
Total 
Stomach 0-2 0-2 0-2 NA 6 
Duodenum 0-2 0-2 0-2 0-2 8 
Colon 0-2 0-2 0-2 NA 6 
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Table 1: Validation study quantitative (scoring 0-2) agreement values (weighted kappa) 
Lesion Stomach Duodenum Colon 
Erosions 0.9 0.9 1.0 
Granularity 1.0 0.66 1.0 
Friability 0.8 0.67 0.78 
Lymphatic dilation NA 0.62 NA 
Total 0.87 0.6 0.71 
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Table 2: Validation study qualitative (lesion present or absent) agreement values (weighted 
kappa) 
Lesion Stomach Duodenum Colon 
Erosions 0.83 0.83 1.0 
Granularity 1.0 0.77 0.8 
Friability 0.91 0.68 0.78 
Lymphatic dilation NA 0.5 NA 
Total 0.87 0.58 0.8 
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CHAPTER 5 
 
GENERAL CONCLUSIONS 
 
The goal of this study was to evaluate inter-observer endoscopic agreement and make 
a simple, novel mucosal endoscopic scoring system for dogs with IBD to help standardize the 
endoscopist’s descriptions of mucosal surfaces. This is the first veterinary study concerning 
this specific topic despite a long history of human medical interest in endoscopic activity 
scores specifically for patients with CD and UC. 
The results of the inter-observer endoscopist agreement using Fleiss kappa statistics 
showed slight to fair agreement within the expert and trainee groups when evaluating the 
stomach, duodenum, and colon mucosa of dogs diagnosed with IBD.  In duodenal assessment, 
there was significant improvement in the trainee endoscopist group when a visual template of 
duodenal lesions were provided with written descriptions of lesions (p<0.01). As a result, the 
trainees scored similarly to the expert endoscopist group.  Therefore, we concluded that 
endoscopists benefitted from clearly defined lesion terminology and visual examples when 
making endoscopic mucosal assessments. 
A simplified endoscopic scoring system was developed based on the results of the 
previous pilot data and numerous human endoscopic indices. Lesions including erosions, 
granularity, and friability were used to describe the stomach, duodenal, and colon mucosal 
surface with the addition of lymphatic dilation when making duodenal assessment. A score of 
0-2 for each lesion in each organ was given; 0=no lesion, 1=mild, and 2=moderate to severe.  
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Total maximum score for the stomach and colon was 6, while the total maximum score for the 
duodenum was 8.  Mild mucosal disease was defined as a total score of 0-2, 3-4=moderate 
disease and 5-6/8=severe disease. Two expert endoscopists evaluated representative video 
clips of a prospective group of dogs with IBD for scoring purposes.  Based on Cohen’s kappa 
statistics, the experts had moderate to almost perfect agreement for stomach, duodenal, and 
colonic mucosal assessments. 
Our recently developed simplified endoscopic mucosal scoring system is easy to use 
and was well received by the endoscopists participating in our study.  The lesions chosen for 
inclusion in the mucosal assessment index were those most often encountered in diseased 
canine GI tracts. A visual template accompanied by written lesion descriptions are useful 
resources for veterinary endoscopists, especially those with limited experience.  We hope that 
the results of this study will further compel fellow clinician scientists to critically evaluate 
how they make endoscopic mucosal assessment in their patients.  A uniform means of 
identifying, describing, and reporting mucosal lesions benefit the patient, fellow veterinarians, 
and will help create more consistent medical record/endoscopy reports. 
 Based on our results, we conclude there is moderate to near perfect agreement of 
expert endoscopists using our simplified mucosal scoring index in dogs with IBD.  Future 
studies are needed to evaluate the significance and association of mucosal lesion assessments 
and other markers for IBD disease severity.  A future study is planned for the comparison of 
our recently developed mucosal endoscopic disease activity score and serum albumin levels, 
histologic assessment, CRP, and pANCA levels. 
